Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.

NCT07044921 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl

Sponsor

Chinese PLA General Hospital